About Us

Archives


Page 11234..1020..»




Cellectis Announces Participation in Five Investor Conferences

Posted: August 29, 2021 at 1:50 am


NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.

Continued here:
Cellectis Announces Participation in Five Investor Conferences

Chalice Brands Ltd. Continues Sequential Revenue Growth

Posted: at 1:49 am


Reports Second Quarter 2021 Revenues of $6.9 Million and Third Consecutive Quarter of Positive Adjusted EBITDA(1)

Link:
Chalice Brands Ltd. Continues Sequential Revenue Growth

CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

Posted: at 1:49 am


Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent approved in 2017)

Read the original post:
CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal…

Posted: at 1:49 am


SHANGHAI, China, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted an investigational new drug application for UBP1213sc, its subcutaneous injection of recombinant humanized anti-BLyS monoclonal antibody.

Go here to see the original:
Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal...

Immunicum Announces Participation in Multiple Upcoming Industry and Investor Events in September and October

Posted: at 1:49 am


Press Release

Read more:
Immunicum Announces Participation in Multiple Upcoming Industry and Investor Events in September and October

Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Posted: at 1:49 am


Media ReleaseCopenhagen, Denmark, 27 August, 2021

Read the original post:
Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

Posted: at 1:49 am


ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

Go here to read the rest:
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

Kraig Biocraft Laboratories Adds European Union to Ever-growing Portfolio of Spider Silk Patents

Posted: at 1:49 am


ANN ARBOR, Mich., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that it has been granted patent protection for its recombinant spider silk technologies in the European Union.

Follow this link:
Kraig Biocraft Laboratories Adds European Union to Ever-growing Portfolio of Spider Silk Patents

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

Posted: at 1:49 am


BERLIN, GERMANY, August 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) agreed today to evaluate the establishment of sustainable vaccine manufacturing capabilities in Rwanda and Senegal to support vaccine supply for the Member States of the African Union. Following the invitation of the kENUP Foundation, President Paul Kagame of Rwanda, President Macky Sall of Senegal, and President Ursula von der Leyen of the European Commission met U?ur ?ahin, CEO and Co-Founder of BioNTech in Berlin to discuss the development of sustainable vaccine production for Africa. The meeting resulted in a joint communiqué affirming BioNTech’s intention to manufacture mRNA vaccines arising from its Malaria and Tuberculosis vaccine development programs on the African continent.

Read the original post:
Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting

Posted: at 1:49 am


BOSTON, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced a poster presentation showcasing initial findings from its ongoing study of ALRN-6924 in healthy volunteers at the International Society for Experimental Hematology (ISEH) 50th Annual Scientific Meeting, which is currently underway. The initial findings demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in healthy, normal bone marrow cells without concurrent induction of apoptosis. The poster can be viewed on Aileron’s website here.

See the original post:
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting

Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil

Posted: at 1:49 am


/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Read the rest here:
Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of…

Posted: at 1:49 am


LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management’s current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D’Alvise as President and Chief Executive Officer, under the oversight of Acasti’s newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.

See the rest here:
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of...

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

Posted: at 1:49 am


Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody molecules to LAG-3 and uses thereof” by the Chinese Patent Office.

Original post:
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

In H1 2021 Olainfarm Group continues stable growth

Posted: at 1:49 am


The compiled financial indicators for the first six months of this year confirm the growth of Olainfarm Group. The financial performance measures of both Olainfarm and its subsidiaries have grown steadily, compared to the same period last year, which means that we are heading in the right direction. The pandemic has not affected our operations significantly either. Russia is still our biggest market, with a significant increase of medicine sales. Ukraine now is in the second place, while the usual second-largest market, Belarus, has dropped to the third position. Overall, financially we are on track with the budget and we are performing well,” J?nis Buks, Chairman of the Management Board of JSC Olainfarm.

Originally posted here:
In H1 2021 Olainfarm Group continues stable growth

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

Posted: at 1:49 am


AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer’s disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.

Continue reading here:
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

Posted: at 1:49 am


Gelsolin immunomodulator treatment associated with patient’s rapid recovery.

Link:
BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer

Posted: at 1:49 am


Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTNBC treatment landscape and in accordance with the requirements of the accelerated approval programme. This decision only impacts the mTNBC indication in the US. It does not affect other approved indications for Tecentriq in the US and outside the US, including mTNBC. This is not related to any changes in either the efficacy or safety associated with Tecentriq.

View post:
Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer

Bone Therapeutics strengthens its financial structure with the implementation of its financing agreement with the European Investment Bank and the…

Posted: at 1:49 am


REGULATORY INFORMATION

Originally posted here:
Bone Therapeutics strengthens its financial structure with the implementation of its financing agreement with the European Investment Bank and the...

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Posted: at 1:49 am


WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the “Court”) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation, Lead Case No. 1:19-cv-10641-LJL (the “Consolidated Derivative Action”).

More here:
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Biomerica Reports Fiscal 2021 Year End Results

Posted: at 1:49 am


IRVINE, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2021 financial results. During the year the Company made significant progress in its business by increasing its number of allowed patents covering its InFoods® diagnostic guided therapy technology, signing a distribution agreement for its H. Pylori product which is expected to be filed with FDA in October, 2021, and has entered into negotiations with major retailers/distributors for sales of its EZ Detect colorectal disease test.

See the original post here:
Biomerica Reports Fiscal 2021 Year End Results

Next Posts »



Page 11234..1020..»